Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma

Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma ANTICANCER RESEARCH Yen, Y., So, S., Rose, M., Saif, M. W., Chu, E., Liu, S., Foo, A., Jiang, Z., Su, T., Cheng, Y. 2009; 29 (10): 4083-4092

Abstract

PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (16.5 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

View details for Web of Science ID 000271487400053

View details for PubMedID 19846955